LIGACHEM BIOSCIENCES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69,000 KRW | +2.53% |
|
+8.32% | +6.15% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,660,235 | 1,352,308 | 1,092,804 | 2,513,487 | - | - |
| Enterprise Value (EV) 1 | 1,660,184 | 1,352,140 | 1,092,804 | 2,513,487 | 2,513,487 | 2,513,487 |
| P/E ratio | -228 x | -57.5 x | -23.2 x | 93.2 x | 199 x | 750 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 33.6 x | 42.1 x | 32.7 x | 18.3 x | 27 x | 17 x |
| EV / Revenue | 33.6 x | 42.1 x | 32.7 x | 18.3 x | 27 x | 17 x |
| EV / EBITDA | -62 x | -54.8 x | -23.8 x | 251 x | -57.8 x | -279 x |
| EV / FCF | -94.2 x | -22.4 x | - | -25.6 x | -62.8 x | 314 x |
| FCF Yield | -1.06% | -4.46% | - | -3.9% | -1.59% | 0.32% |
| Price to Book | 14.8 x | 5.23 x | - | 4 x | 5.73 x | 3.9 x |
| Nbr of stocks (in thousands) | 23,684 | 24,235 | 25,503 | 36,427 | - | - |
| Reference price 2 | 70,100 | 55,800 | 42,850 | 69,000 | 69,000 | 69,000 |
| Announcement Date | 3/16/21 | 3/23/22 | 3/15/23 | - | - | - |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 49.39 | 32.16 | 33.41 | 137 | 93 | 148 |
| EBITDA 1 | -26.77 | -24.66 | -45.91 | 10 | -43.5 | -9 |
| EBIT 1 | -29.76 | -27.71 | -50.23 | 6 | -47.5 | -13 |
| Operating Margin | -60.25% | -86.16% | -150.34% | 4.38% | -51.08% | -8.78% |
| Earnings before Tax (EBT) 1 | -8.827 | -20.52 | -47.58 | 26 | -40 | 3 |
| Net income 1 | -6.986 | -23.39 | -44.95 | 26 | -37.5 | 3 |
| Net margin | -14.14% | -72.74% | -134.53% | 18.98% | -40.32% | 2.03% |
| EPS 2 | -307.0 | -970.0 | -1,845 | 740.0 | 346.0 | 92.00 |
| Free Cash Flow 3 | -17,633 | -60,358 | - | -98,000 | -40,000 | 8,000 |
| FCF margin | -35,698.54% | -187,696.99% | - | -71,532.85% | -43,010.75% | 5,405.41% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | 266,666.67% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/21 | 3/23/22 | 3/15/23 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | 51 | 168 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -17,633 | -60,358 | - | -98,000 | -40,000 | 8,000 |
| ROE (net income / shareholders' equity) | -6.13% | -12.6% | - | 6.6% | -18.8% | 0.5% |
| ROA (Net income/ Total Assets) | -5.04% | -10.9% | - | 19% | -34.3% | - |
| Assets 2 | 138.7 | 214.6 | - | 136.8 | 109.3 | - |
| Book Value Per Share 3 | 4,734 | 10,678 | - | 17,270 | 12,047 | 17,704 |
| Cash Flow per Share 3 | - | - | - | 1,881 | -2,963 | - |
| Capex 2 | 2.74 | 18.3 | - | 2 | 3.5 | 2 |
| Capex / Sales | 5.55% | 56.94% | - | 1.46% | 3.76% | 1.35% |
| Announcement Date | 3/16/21 | 3/23/22 | 3/15/23 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.15% | 1.82B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- A141080 Stock
- Financials LigaChem Biosciences Inc.
